Verseon (LSE:VERS) Cash, Cash Equivalents, Marketable Securities : £1.79 Mil (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Cash, Cash Equivalents, Marketable Securities?

Verseon's quarterly cash, cash equivalents, marketable securities declined from Jun. 2018 (£14.47 Mil) to Dec. 2018 (£2.88 Mil) but then stayed the same from Dec. 2018 (£2.88 Mil) to Jun. 2019 (£1.79 Mil).

Verseon's annual cash, cash equivalents, marketable securities declined from Dec. 2016 (£37.54 Mil) to Dec. 2017 (£8.67 Mil) and declined from Dec. 2017 (£8.67 Mil) to Dec. 2018 (£2.88 Mil).

Verseon Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Verseon's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Cash, Cash Equivalents, Marketable Securities Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

0.01

49.88

37.54

8.67

2.88

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial									24.06	8.67	14.47	2.88	1.79

Verseon Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Verseon (LSE:VERS) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Verseon Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Verseon's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.